William E. Boden, MD, discusses his research in which he and his colleagues tried to replicate the results seen in the REDUCE-IT trial. His research was also presented at ACC.19 Scientific Session.
William E. Boden, MD, is a professor of medicine at Boston University School of Medicine and a lecturer in medicine at Harvard Medical School. He is also the Physician Research Lead & Scientific Director of the Clinical Trials Network in the VA New England Healthcare System in Boston, Massachusetts. Read his research here.
References:
Leatherman S, Ferguson R, Weir I, et al. Increased residual cardiovascular risk in US veterans and moderately elevated baseline triglycerides and well-controlled LDL-C levels on statins. Paper presented at: ACC.19 Scientific Session; March 16-18, 2019; New Orleans, LA. https://www.abstractsonline.com/pp8/#!/5758/presentation/40044. Accessed April 18, 2019.
Bhatt DL, Steg G, Miller M, et al; the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia [published online November 10, 2018]. N Engl J Med. doi:10.1056/NEJMoa1812792.
